Skip to main content
SpringerLink
Log in

Medikamentöse versus invasive Blutdrucktherapie

Haben interventionelle Hochdruckverfahren eine Zukunft?

  • Zertifizierte Fortbildung
  • Schwerpunkt Hypertonie
  • Published:
CardioVasc Aims and scope

Zusammenfassung

Invasive Verfahren sind kein ultimatives Allheilmittel in der Hypertonietherapie, sie senken den Blutdruck nur moderat und sind deutlich teurer als die medikamentöse Therapie. Trotzdem haben sie ihre Daseinsberechtigung, denn in besonderen Fällen sehen wir nach wie vor die Indikation für invasive Hochdruckverfahren gegeben.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Peet MM. Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy. Am J Surg. 1948;75:48–68

    Article  CAS  Google Scholar 

  2. Hoobler SW et al. The effects of splanchnicectomy on the blood pressure in hypertension; a controlled study. Circulation. 1951;4:173–83

    Article  CAS  Google Scholar 

  3. Symplicity HTNI, Esler MD et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–9

    Article  Google Scholar 

  4. Krum H et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622–9

    Article  Google Scholar 

  5. Cuspidi C et al. Treatment of hypertension: The ESH/ESC guidelines recommendations. Pharmacol Res. 2018;128:315–321

    Article  Google Scholar 

  6. Townsend RR et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160–70

    Article  Google Scholar 

  7. Azizi M et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–45

    Article  Google Scholar 

  8. Rosa J et al. Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study. Hypertension. 2016;67:397–403

    Article  CAS  Google Scholar 

  9. Ott C, et al. Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol. 2013;62:1880–6

    Article  Google Scholar 

  10. Zweiker D et al. Effects of Renal Denervation Documented in the Austrian National Multicentre Renal Denervation Registry. PLoS One. 2016;11:e0161250

    Article  Google Scholar 

  11. Schmieder RE et al. Disproportional decrease in office blood pressure compared with 24-hour ambulatory blood pressure with antihypertensive treatment: dependency on pretreatment blood pressure levels. Hypertension. 2014;64:1067–72

    Article  CAS  Google Scholar 

  12. Courand PY et al. Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial. J Am Heart Assoc. 2017;6(10). https://doi.org/10.1161/JAHA.117.007062.

    Google Scholar 

  13. Kandzari DE et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36:219–27

    Article  Google Scholar 

  14. Reshetnik A et al. Predictors for success in renal denervation-a single centre retrospective analysis. Sci Rep. 2018;8:15505

    Article  Google Scholar 

  15. Lobo MD et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet. 2015;385:1634–41

    Article  Google Scholar 

  16. Wallbach M et al. Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension. Hypertension. 2016;67(4):701–9

    Article  CAS  Google Scholar 

  17. Bisognano JD et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58:765–73.

    Article  Google Scholar 

  18. Wachter R et al. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. J Am Soc Hypertens. 2017;11:81–91

    Article  Google Scholar 

  19. Spiering W et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet. 2017;390:2655–61

    Article  Google Scholar 

  20. Kandzari DE et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–55

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Charité — Universitätsmedizin Berlin, Campus Benjamin Franklin, CharitéCentrum 13 — Schwerpunkt Nephrologie, Transplantationszentrum/Hypertoniezentrum, Hindenburgdamm 30, 12203, Berlin, Deutschland

    Christopher Gohlisch &  Alexander Reshetnik

Authors
  1. Christopher Gohlisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Reshetnik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Reshetnik.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen und dass keine potenziellen Interessenkonflikte vorliegen. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gohlisch, C., Reshetnik, A. Haben interventionelle Hochdruckverfahren eine Zukunft?. CV 19, 33–38 (2019). https://doi.org/10.1007/s15027-019-1449-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-019-1449-9

Search

Navigation